Ignite Creation Date:
2024-05-06 @ 7:55 PM
Last Modification Date:
2024-10-26 @ 3:16 PM
Study NCT ID:
NCT06184360
Status:
COMPLETED
Last Update Posted:
2023-12-28
First Post:
2023-12-14
Brief Title:
Real-world Evaluation of BEOVU Brolucizumab Effectiveness and Durability for Treatment of Neovascular Wet Age-related Macular Degeneration AMD
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
Real-world Evaluation of BEOVU Brolucizumab Effectiveness and Durability for Treatment of Neovascular Wet Age-related Macular Degeneration AMD
Status:
COMPLETED
Status Verified Date:
2023-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This was a retrospective observational cohort study Data were analyzed from the Intelligent Research in Sight IRIS registry from October 8 2019 through November 26 2021 with a follow-up period of 12 months following the first brolucizumab injection index date
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None